Outlook Therapeutics vs Scholar Rock
OTLK and SRRK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How OTLK and SRRK compare
Scholar Rock is the larger company, worth 63 times as much as Outlook Therapeutics ($5.5B against $87.8M).
Outlook Therapeutics scores higher on the StockData Score (4 against 2 for Scholar Rock), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | OTLK | SRRK |
|---|---|---|
| Size and price | ||
| Market cap | $87.8M | $5.5B |
| Share price | $0.361 | $45.08 |
| Change, 1 year | −77.0% | 20.5% |
| Change, 5 years | −98.7% | 67.1% |
| Beta (5Y) | 3.72 | 0.83 |
| Employees | 17 | 289 |
| StockData Score | ||
| Total score | 4 (better) | 2 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 4 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | – | 21.6× |
| FCF yield | – | −5.4% |
| Profitability | ||
| Return on equity | – | −168% |
| Financial health | ||
| Debt / equity | – | 0.77 |
| Interest coverage | – | −38.0× |
| Current ratio | 0.81 | 7.02 (better) |
| Altman Z-score | −40.77 | 6.59 (better) |
| Piotroski F-score | 1 | 1 |
| Dividends and buybacks | ||
| Buyback yield | −62.3% | −4.6% (better) |
| Shareholder yield | −62.3% | −4.6% (better) |
| Ownership | ||
| Held by institutions | 8.4% | 114% |
| Held by insiders | 28.5% | 28.9% |
| Insider net buying, 12 months | $7.9M (better) | −$7.4M |
| Short interest, % of float | 20.4% | 27.1% |
Go deeper
- OTLK stock overview
- OTLK income statement
- OTLK valuation and score
- SRRK stock overview
- SRRK income statement
- SRRK valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.